Respiratory syncytial virus infection in anti-mu-treated mice

J Virol. 1991 Sep;65(9):4936-42. doi: 10.1128/JVI.65.9.4936-4942.1991.

Abstract

BALB/c mice were depleted of B cells by anti-mu treatment to investigate the pathogenesis of respiratory syncytial virus (RSV) infection in the absence of antibody. Termination of RSV replication after primary infection occurred with the same kinetics in anti-mu-treated mice as in phosphate-buffered saline (PBS)-treated controls. Yet, when rechallenged, anti-mu-treated mice were more permissive to RSV replication than PBS-treated controls. Anti-mu-treated mice also experienced greater illness than PBS-treated controls during both primary infection and rechallenge. Passive transfer of RSV-specific immune serum to anti-mu-treated mice before rechallenge reconstituted complete protection from RSV replication and diminished illness. Thus, RSV-specific antibody is not required to terminate RSV replication in primary infection, but without antibody, only partial immunity against rechallenge is induced. While it is unknown whether the mechanism is a direct effect on RSV titer or modulation of the illness-causing cellular immune response, the presence of RSV-specific antibody reduces illness in both primary RSV infection and rechallenge of mice.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Anti-Idiotypic / immunology
  • Antibodies, Viral / immunology
  • Antibody Formation
  • B-Lymphocytes / immunology*
  • Immunoglobulin mu-Chains / immunology
  • Immunologic Memory
  • Lung / pathology
  • Mice
  • Mice, Inbred BALB C
  • Respiratory Syncytial Viruses / growth & development*
  • Respiratory Syncytial Viruses / immunology
  • Respirovirus Infections / immunology*
  • Respirovirus Infections / pathology

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Viral
  • Immunoglobulin mu-Chains